Colorectal cancer 1

Common Name(s)

Colorectal cancer 1

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Colorectal cancer 1" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Colorectal cancer 1" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Colorectal cancer 1" returned 348 free, full-text research articles on human participants. First 3 results:

Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.
 

Author(s): Johanna C Bendell, Lee S Rosen, Robert J Mayer, Jonathan W Goldman, Jeffrey R Infante, Fabio Benedetti, Donghu Lin, Hirokazu Mizuguchi, Christopher Zergebel, Manish R Patel

Journal: Cancer Chemother. Pharmacol.. 2015 Nov;76(5):925-32.

 

To evaluate safety of TAS-102 administered twice daily (bid) on days 1-5 and 8-12 of a 4-week cycle, confirm feasibility of the Japanese recommended dose (RD), 35 mg/m(2), in Western patients with metastatic colorectal cancer (mCRC) refractory to standard chemotherapies, and describe ...

Last Updated: 21 Oct 2015

Go To URL
Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples.
 

Author(s): D S Thomas, E-O Fourkala, S Apostolidou, R Gunu, A Ryan, I Jacobs, U Menon, W Alderton, A Gentry-Maharaj, J F Timms

Journal: Br. J. Cancer. 2015 Jul;113(2):268-74.

 

Blood-borne biomarkers for early detection of colorectal cancer (CRC) could markedly increase screening uptake. The aim of this study was to evaluate serum carcinoembryonic antigen (CEA), CYFRA21-1 and CA125 for the early detection of CRC in an asymptomatic cohort.

Last Updated: 15 Jul 2015

Go To URL
MicroRNA-217 functions as a prognosis predictor and inhibits colorectal cancer cell proliferation and invasion via an AEG-1 dependent mechanism.
 

Author(s): Bo Wang, Zhan-Long Shen, Ke-Wei Jiang, Gang Zhao, Chun-You Wang, Yi-Chao Yan, Yang Yang, Ji-Zhun Zhang, Chao Shen, Zhi-Dong Gao, Ying-Jiang Ye, Shan Wang

Journal:

 

Recent studies have indicated the possible function of miR-217 in tumorigenesis. However, the roles of miR-217 in colorectal cancer (CRC) are still largely unknown.

Last Updated: 28 May 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Colorectal cancer 1" returned 3 free, full-text review articles on human participants. First 3 results:

STAT3 and sphingosine-1-phosphate in inflammation-associated colorectal cancer.
 

Author(s): Andrew V Nguyen, Yuan-Yuan Wu, Elaine Y Lin

Journal: World J. Gastroenterol.. 2014 Aug;20(30):10279-87.

 

Accumulated evidences have demonstrated that signal transducer and activator of transcription 3 (STAT3) is a critical link between inflammation and cancer. Multiple studies have indicated that persistent activation of STAT3 in epithelial/tumor cells in inflammation-associated colorectal ...

Last Updated: 18 Aug 2014

Go To URL
Antineoplastic effects of 1,25(OH)2D3 and its analogs in breast, prostate and colorectal cancer.
 

Author(s): Carlien Leyssens, Lieve Verlinden, Annemieke Verstuyf

Journal:

 

The active form of vitamin D3, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), is mostly known for its importance in the maintenance of calcium and phosphate homeostasis. However, next to its classical effects on bone, kidney and intestine, 1,25(OH)2D3 also exerts antineoplastic effects on ...

Last Updated: 25 Mar 2013

Go To URL
Molecular staging of colorectal cancer in African-American and Caucasian patients using phenotypic expression of p53, Bcl-2, MUC-1 AND p27(kip-1).
 

Author(s): William E Grizzle, Upender Manne, Heide L Weiss, Nirag Jhala, Lynya Talley

Journal: Int. J. Cancer. 2002 Feb;97(4):403-9.

 

The gold standard for clinical outcome of most cancers has been the clinical and pathologic staging of the tumors after surgery. For colorectal cancer (CRC), nodal involvement at the time the primary tumor is resected has been the most reliable indicator of clinical outcome; however, ...

Last Updated: 21 Jan 2002

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Last Updated: 1 Sep 2010

Go to URL
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions)
 

Status: Recruiting

Condition Summary: Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Melanoma; Neuroendocrine Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Primary Brain Tumors; Renal Cell Carcinoma; Sarcomas; Salivary Gland Cancers; Adult Solid Tumor

 

Last Updated: 8 Feb 2016

Go to URL
Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety and Efficacy Profiles of TSB-9-W1
 

Status: Not yet recruiting

Condition Summary: Metastatic Colorectal Cancer

 

Last Updated: 11 May 2015

Go to URL